No Data
YESTAR HEALTH: ANNUAL REPORT 2024
YESTAR HEALTH (02393): Wang Chunlai has been appointed as Executive Director.
YESTAR HEALTH (02393) announced that Mr. Wang Chunlai (Mr. Wang) has been appointed as the Executive Director of the company,...
Express News | Yestar Healthcare - Liao Changxiang Tendered Her Resignation as Chief Executive Officer
Express News | Yestar Healthcare - Wang Chunlai Appointed as an Executive Director
YESTAR HEALTH (02393.HK) reported a 17.3% decrease in revenue for the year 2024, down to 2.41 billion yuan.
Gelonghui reported on March 28 that YESTAR HEALTH (02393.HK) announced that the group's overall revenue for the fiscal year 2024 decreased by 17.3% year-on-year to RMB 2,409.9 million. The gross margin of the business fell from 17.6% to 16.6%, mainly due to the impact of the national centralized procurement policy. The profit attributable to shareholders from continuing operations for the year was approximately RMB 921.1 million (2023: loss of RMB 9.3 million).
Express News | Yestar Healthcare Holdings FY Revenue Continuing Operations RMB 2,409.9 Million
